Pomerantz LLP filed a class action lawsuit against Insulet Corporation on July 3, 2026. The complaint alleges that Insulet and its officers violated federal securities laws. The class period includes investors who purchased securities between February 21, 2025, and May 26, 2026.
The lawsuit links stock price drops on March 13, 2026, and May 27, 2026, to specific product disclosures. Insulet issued voluntary Medical Device Corrections for its Omnipod products due to potential insulin under-delivery. The complaint alleges the company made material misrepresentations and omissions regarding these defects.
The deadline for investors to move for lead plaintiff is August 31, 2026.